Part VI — Peptide Science and Technology

Chapters 32–36

Everything up to this point has treated peptides as things that exist. Part VI asks where they come from — and the answers turn out to settle several arguments that biology alone could not.

Four questions run through these five chapters:

How is a peptide actually made? Not in theory. Physically, in a facility, at scale, at a cost.

How is one improved? Native peptides are poor drugs. Every successful peptide medicine has been modified, and the modification toolkit is small, elegant, and worth knowing.

How does anyone know what is in a vial? This is a chemistry question with an unusually direct bearing on the questions raised in Part III.

And where do new ones come from? Increasingly, from screening billions of candidates or generating them computationally rather than finding them in an organism.

The five chapters

Chapter 32 — How Peptides Are Made starts with an idea from 1963 that made the whole field practical: anchor the growing chain to a solid bead, then wash everything else away. Solid-phase peptide synthesis is simple to describe and unforgiving in the arithmetic — if each of forty coupling steps succeeds 99% of the time, the yield of correct full-length product is about 67%, and the other third is a mixture of near-misses that look almost identical. The chapter also covers recombinant production (how insulin is made), why the choice between them is mostly about length and volume, and the honest cost stack behind a peptide drug's price.

Chapter 33 — Peptide Engineering is the modification toolkit: substituting an unnatural amino acid so an enzyme cannot recognize the cut site; using D-amino acids, which are mirror images that proteases cannot process; cyclizing a peptide so it cannot unfold; stapling a helix so it holds its shape; attaching a fatty acid so the molecule binds albumin and rides in circulation for a week instead of a minute. This is where the semaglutide anchor gets drawn in full, and where you see that the drug is the delivery solution as much as it is the molecule.

Chapter 34 — Peptide Analysis and Quality Control is the chapter Part III has been pointing at. Mass spectrometry tells you what a molecule weighs, which tells you a great deal about what it is. HPLC tells you how many different things are in the sample and in what proportion. Neither tells you whether it is sterile, whether it contains endotoxin, or whether the material in the vial you received is the material that was tested. The chapter teaches you to read a certificate of analysis — the six things it can establish, and the four it cannot — and returns to the four vials from Chapter 6.

Chapter 35 — Peptide Discovery covers the four routes to a new peptide drug: isolate it from an organism, evolve it in the laboratory (phage display, recognized with a Nobel Prize in 2018), design it from a structure, or generate it computationally. The chapter is careful about what AlphaFold and its successors actually changed, which is a great deal, and what they did not, which is also a great deal. Discovery is no longer the bottleneck in this field. Delivery, manufacturing, and clinical validation are.

Chapter 36 — The Future of Peptide Medicine is the forward look, with the book's standing discipline applied to it: oral delivery and permeation enhancers, peptide-drug conjugates, cell-penetrating peptides, long-acting implants, peptides as targeting addresses for gene therapy, and the biosimilar price cliff coming for the GLP-1 class. Everything here is explicitly rated 🔬 or ⚠️, and the chapter says plainly which predictions are extrapolations and which are press releases.

Why the technology chapters matter more than they look

Because manufacturing explains the shortage. The GLP-1 supply constraint that reorganized an entire market was not a business decision. It was aseptic fill-finish capacity and injector-pen assembly. Chapter 32 makes that concrete.

Because analysis explains the gray market. Once you know what mass spectrometry and HPLC actually measure, "third-party tested" stops being reassuring and starts being a question: tested for what, by whom, on which batch, and does the certificate correspond to the vial in your hand? Chapter 34 turns a vague unease into six specific checks.

Because engineering explains the price. A peptide that is expensive to synthesize, unstable in solution, and requires cold-chain distribution costs what it costs partly for reasons that have nothing to do with monopoly pricing — and partly for reasons that have everything to do with it. Chapter 32 separates the two honestly.

And because discovery explains the pipeline. When a company announces an AI-designed peptide, you will know what was actually automated, what still requires eight years and a Phase III program, and which part of the sentence is doing the marketing.

A note for readers who skipped ahead

If you arrived here from Part III because you wanted to know whether the vial in your refrigerator is what the label says, read Chapter 34 first. It is written to stand alone for exactly that reason, and it is the most practically useful chapter in Part VI.

Then come back to Chapter 32, because the answer to "how could a vial contain the wrong thing?" is mostly a manufacturing answer, and it is more interesting than you would expect.

📋 Your Evidence Dossier — Part VI

Chapter 34 completes Field 10 (Status) with the part most dossiers leave blank: the quality-risk line. Not "is this legal" but "how would I know what this actually is, and what would that knowledge still fail to tell me?"

Chapter 35 sharpens Field 12 from a vague hope into a specification: not "if there were more research," but what design, what population, what endpoint, what duration would actually move this rating. A Field 12 you could hand to a trialist is a Field 12 that means something.

Chapters in This Part